SynthesisNeurosurgical review2026
Assessment of venous thromboembolism in adult-type diffuse gliomas at a quaternary neuro-oncology center: a retrospective cross-sectional study and systematic review.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) remains a clinically relevant and impactful complication in patients with adult-type diffuse gliomas, and its overall frequency and determinants remain poorly defined. We retrospectively examined 147 patients with gliomas treated at a Brazilian quaternary neuro-oncology center during 2018–2023 and performed a Preferred Reporting Items for Systematic Reviews and Meta-Analysis/Synthesis without Meta-Analysis–based systematic review of observational studies (incorporating eight cohorts; N = 7779) published since 2015. The patients’ median age at diagnosis was 55 (range 20–86) years. Glioblastoma was the predominant glioma type (n = 91, 61.9%), followed by astrocytoma (n = 32, 21.8%) and oligodendroglioma (n = 24, 16.3%). VTE events occurred in 5 (3.4%) patients, 4 (80%) with isocitrate dehydrogenase (IDH)–wild-type glioblastoma (5.6% incidence within this subgroup) and 1 (20%) with IDH-mutant astrocytoma; no thrombosis was identified in patients with oligodendrogliomas. All five events (three pulmonary thromboembolism [PTE] and two lower-limb deep-vein thrombosis [DVT]) events) occurred within 6 months of surgery, clustered in patients aged between 41 and 60 years and evenly distributed by sex. Cerebral venous thrombosis (CVT) was not observed. In the systematic review, the VTE incidence rate was 6.2%–31% in grade 4 gliomas and 1.4%–5.2% in grades 2 and 3. DVT comprised 60% of thromboembolic events; PTE, 35%; and CVT, 5%. Poor performance status, a surgery duration of > 4 h, and bevacizumab exposure increased the risk for VTE, whereas IDH mutation reduced it by ~ 70%. The median time from surgery to VTE diagnosis was 21–90 days, and 30-day mortality after VTE was 7%–15%. Findings show that large, prospective, multicenter, molecularly annotated glioma cohorts remain vital for thrombosis risk stratification and targeted prophylactic strategy development.Clinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.